Wellgistics Health (NASDAQ: WGRX) Targets \$70B+ GLP-1 Market With Launch of Forzet™: A Potential Game-Changer for Muscle Loss Management

Key Points

• Launch of Forzet™: Wellgistics Health, Inc. announces the launch of Forzet™, a proprietary medical food targeting muscle loss associated with GLP-1 agonist therapies (e.g., Ozempic®, Wegovy®, Mounjaro®).
• Market Opportunity: The GLP-1 agonist market is projected to grow from \$70 billion in 2025 to \$201 billion in 2030, creating a massive opportunity for adjunct solutions addressing drug side effects.
• Unique Value Proposition: Forzet™ is designed to preserve muscle mass in patients undergoing GLP-1 therapy, potentially improving therapy adherence and minimizing post-therapy weight regain.
• Clinical Validation: Forzet’s formulation has been evaluated in multiple controlled studies, including in Type 2 diabetes, heart failure, and COPD populations in Europe.
• Regulatory Status and Availability: Classified as a medical food (not an FDA-approved drug), Forzet™ is available over the counter, does not require a prescription, and is to be dispensed through Wellgistics’ pharmacy network.
• Commercialization Strategy: Wellgistics plans to leverage its proprietary AI platform (EinsteinRx™) and blockchain-enabled PharmacyChain™ to recommend Forzet™ at point of sale and through direct-to-consumer (DTC) and telehealth channels.

Detailed Report for Investors

TAMPA, FL, March 9, 2026 – Wellgistics Health, Inc. (NASDAQ: WGRX), a leader in health information technology, has announced the launch of its proprietary medical food, Forzet™, aimed squarely at one of the most significant and growing challenges in the weight loss therapy market: muscle loss caused by GLP-1 agonist drugs.

GLP-1 drugs such as Ozempic®, Wegovy®, and Mounjaro® have rapidly become the fastest-growing drug class globally, due to their effectiveness in supporting weight loss and combating associated diseases. However, a major side effect—loss of muscle mass—has emerged as a limiting factor for patient adherence and long-term success of these therapies. According to Grandview Research, the GLP-1 agonist market is expected to nearly triple in size over the next five years, from \$70 billion in 2025 to \$201 billion in 2030, driven by increased potency, more convenient oral formulations, and growing demand from non-obese populations seeking weight management alternatives.

Forzet™ is being positioned as a first-in-class adjunct solution to address this unmet need. Its proprietary formulation is reported to have significant clinical validation, including use in controlled studies among patients with Type 2 diabetes, heart failure, and COPD in Europe. The product is classified as a “Food for Special Medical Purposes” under U.S. regulations, intended for the dietary management of muscle loss associated with weight loss therapies, and is available over the counter under physician supervision.

Commercialization and Distribution: Forzet™ will initially be dispensed through Wellgistics’ affiliated pharmacies and select members of its extensive Pharmacy Network, which currently includes over 6,500 pharmacies and 200+ manufacturers. The company will also utilize its AI-driven EinsteinRx™ platform to prompt pharmacists to recommend Forzet™ at the point of sale for patients prescribed GLP-1 drugs. Further, Wellgistics plans to make Forzet™ a central feature of its direct-to-consumer and telehealth offerings, aiming to drive patient loyalty and expand its DTC footprint.

Market Differentiation: Unlike traditional dietary supplements, Forzet™ is supported by a robust clinical data package and is produced under stringent manufacturing standards, distinguishing it as a medical food. This positioning may facilitate acceptance among healthcare professionals and patients seeking evidence-based solutions to muscle loss—a key concern with GLP-1 therapies.

Dr. Vivek Bansal, a triple board-certified endocrinologist and founder of The EnLyv Clinics, commented on the launch, stating that his practice has observed the challenge of muscle loss in patients on weight loss therapies and that Forzet™ represents a promising solution that has performed well in other muscle loss-related conditions. (Dr. Bansal is independent and was not compensated for his statement.)

Potential Shareholder Impact & Price Sensitivity

• Significant Market Opportunity: The rapid growth of the GLP-1 market and Wellgistics’ early-mover advantage with a clinically supported adjunct solution could position the company for substantial revenue growth, if adoption rates meet expectations.
• Innovative Technology Integration: The integration of Forzet™ into Wellgistics’ AI-driven and blockchain-enabled platforms could improve patient outcomes, streamline pharmacy operations, and enhance competitive differentiation.
• Expansion into DTC and Telehealth: The company’s plan to build out direct telehealth and DTC channels for GLP-1 drugs and Forzet™ could provide new revenue streams and increase patient capture, further supporting share value.
• Regulatory and Market Risks: As Forzet™ is a medical food (not an FDA-approved drug), its commercialization is subject to regulatory and compliance scrutiny. The company explicitly notes risks related to market acceptance, regulatory changes, and competition, all of which could materially impact performance.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is a health IT leader focused on optimizing the prescription drug dispensing journey for independent pharmacies through AI, blockchain, digital prescription routing, and direct-to-patient delivery. Its network connects 6,500+ pharmacies and 200+ manufacturers, providing end-to-end, transparent solutions for the U.S. prescription drug market.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This article contains “forward-looking statements” regarding Wellgistics Health’s future performance, product commercialization, market opportunity, and strategic initiatives. Actual results may differ materially due to risks including, but not limited to, commercialization success, regulatory changes, competition, and market acceptance. Investors should review Wellgistics Health’s filings with the SEC for a discussion of risk factors. This article does not constitute investment advice. Wellgistics makes no representation that Forzet™ diagnoses, treats, cures, or prevents any disease.

View Wellgistics Health, Inc. Historical chart here